title: Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.
abstract: Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.
authors.affiliation: Min Su Kim, Young-Joo Jin, Jin-Woo Lee, Jung-il Lee, Young soo Kim, Sun young Lee, Myoung Hun Chae, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 400-711, South Korea.
authors.forename: Min Su
authors.initials: MS
authors.lastname: Kim
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Jin
authors.forename: Jin-Woo
authors.initials: JW
authors.lastname: Lee
authors.forename: Jung-Il
authors.initials: JI
authors.lastname: Lee
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Kim
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Lee
authors.forename: Myoung Hun
authors.initials: MH
authors.lastname: Chae
keywords: Complete remission; Hepatocellular carcinoma; Portal vein thrombosis; Sorafenib
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Target Oncol. 2010 Mar;5(1):59-63
references.pmid: 20309643
references.citation: Med Oncol. 2011 Dec;28 Suppl 1:S165-8
references.pmid: 20809183
references.citation: Gut Liver. 2010 Sep;4(3):423-7
references.pmid: 20981227
references.citation: World J Gastroenterol. 2006 Dec 21;12(47):7561-7
references.pmid: 17171782
references.citation: Hepatology. 1999 Jan;29(1):62-7
references.pmid: 9862851
references.citation: J Exp Clin Cancer Res. 2006 Sep;25(3):403-9
references.pmid: 17167981
references.citation: Onkologie. 2007 Oct;30(10):519-24
references.pmid: 17890892
references.citation: Oncologist. 2008 Sep;13(9):1001-11
references.pmid: 18779536
references.citation: Hepatology. 2000 Aug;32(2):233-8
references.pmid: 10915729
references.citation: BMC Gastroenterol. 2011 Jan 17;11:4
references.pmid: 21241463
references.citation: J Gastroenterol. 2006 Nov;41(11):1099-106
references.pmid: 17160521
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Oncology. 2011;81 Suppl 1:152-7
references.pmid: 22212950
references.citation: J Gastroenterol Hepatol. 2001 Jun;16(6):660-5
references.pmid: 11422619
references.citation: Am J Gastroenterol. 2009 Jul;104(7):1852-4
references.pmid: 19574982
references.citation: Cancer Res. 2006 Dec 15;66(24):11851-8
references.pmid: 17178882
references.citation: J Hepatol. 2004 Nov;41(5):864-80
references.pmid: 15519663
references.citation: Am J Clin Oncol. 2002 Apr;25(2):189-93
references.pmid: 11943901
references.citation: Cancer Chemother Pharmacol. 2013 Jan;71(1):165-73
references.pmid: 23079897
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Lancet. 2003 Dec 6;362(9399):1907-17
references.pmid: 14667750